Annotation Detail
Information
- Associated Genes
- AREG
- Associated Variants
-
AREG EXPRESSION
AREG EXPRESSION - Associated Disease
- colorectal cancer
- Source Database
- CIViC Evidence
- Description
- 226 cetuximab-treated patients with colorectal cancer (CRC) were analyzed for mRNA expression (by qPCR) of EGFR and its ligands (EGF, TGFA, AREG and EREG). High AREG mRNA expression in KRAS wild type tumours was a favorable predictor in a multivariate analysis (median survival 33 vs. 15 months, p=0.0005). Cetuximab-treated patients with AREG-low KRAS wild type CRC had poor survival, similar to KRAS mutated CRC.
- Variant Origin
- N/A
- Variant Origin
- N/A
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/788
- Gene URL
- https://civic.genome.wustl.edu/links/genes/389
- Variant URL
- https://civic.genome.wustl.edu/links/variants/315
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Colorectal Cancer
- Evidence Direction
- Supports
- Drug
- Cetuximab
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 23374602
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Cetuximab | Sensitivity | true |